I'm really optimistic about NRX because of the massive potential in the spinal injury market and their innovative ExoPTEN nanodrug. With the increasing M&A activity and NRX's promising technology, I see a strong case for it becoming a takeover target, which could drive significant price appreciation.

Nurexone Biologics is on course for significant growth in regenerative medicine, with promising results from preclinical trials and expanding market potential. The recent bullish Golden Cross signal suggests a positive trend change in the stock price.